Legal & General Group
VYNE icon

Legal & General Group’s VYNE Therapeutics VYNE Stock Holding History

Legal & General Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-179
Closed -$22K – 3657
2021
Q1 		$22K Hold
179
– – ﹤0.01% 3106
2020
Q4 		$20K Hold
179
– – ﹤0.01% 3095
2020
Q3 		$21K Sell
179
-17
-9% -$1.98K ﹤0.01% 2959
2020
Q2 		$24K Buy
196
+112
+133% +$15.2K ﹤0.01% 2990
2020
Q1 		$16K Buy
84
+47
+127% +$14.7K ﹤0.01% 3004
2019
Q4 		$12K Hold
37
– – ﹤0.01% 3272
2019
Q3 		$12K Hold
37
– – ﹤0.01% 3245
2019
Q2 		$16K Buy
37
+21
+131% +$10.4K ﹤0.01% 3269
2019
Q1 		$9K Hold
16
– – ﹤0.01% 3264
2018
Q4 		$5K Hold
16
– – ﹤0.01% 3338
2018
Q3 		$11K Hold
16
– – ﹤0.01% 3315
2018
Q2 		$9K Hold
16
– – ﹤0.01% 3313
2018
Q1 		$43K Buy
+16
New +$38.9K ﹤0.01% 2826

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Legal & General Group's VYNE Position: Q2 2021 in Review

Legal & General Group sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 179 shares — an estimated $22K sold.

Legal & General Group first reported a position in VYNE in Q1 2018 and held it in 13 quarters. The position peaked at $43K in Q1 2018. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

  • Legal & General Group reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 179 VYNE Therapeutics shares in Q2 2021, an estimated $22K.
  • Legal & General Group first reported a position in VYNE Therapeutics in Q1 2018 and held it in 13 quarters.
  • Legal & General Group's VYNE Therapeutics position peaked at $43K in Q1 2018.
  • 72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.